Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 10/20 | 0.60 |
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | CASP2 | P42575 | 1/20 | 0.54 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.50 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5525420 | 0.98 | EPHX1 (0.64) | EPHX1NAAACASP2ZDHHC20ZDHHC2 | |
| SCHEMBL5524972 | 0.93 | — | — | |
| SCHEMBL535449 | 0.85 | — | — | |
| SCHEMBL1198895 | 0.79 | EPHX1 (0.58) | EPHX1NAAACASP2ZDHHC20ZDHHC2 | |
| SCHEMBL30327641 | 0.79 | EPHX1 (0.58) | EPHX1NAAACASP2ZDHHC20ZDHHC2 | |
| SCHEMBL8950854 | 0.77 | EPHX1 (0.61) | EPHX1NAAACASP2ZDHHC20ZDHHC2 | |
| SCHEMBL9175710 | 0.77 | EPHX1 (0.61) | EPHX1NAAACASP2ZDHHC20ZDHHC2 | |
| SCHEMBL8950810 | 0.77 | EPHX1 (0.61) | EPHX1NAAACASP2ZDHHC20ZDHHC2 | |
| SCHEMBL8950762 | 0.77 | EPHX1 (0.61) | EPHX1NAAACASP2ZDHHC20ZDHHC2 | |
| SCHEMBL14873909 | 0.77 | EPHX1 (0.56) | EPHX1NAAACASP2ZDHHC20ZDHHC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1698626-A1 | AMIDOPYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-6331555-B1 | EVALUATING SUSCEPTIBILITY OF CANCER TO COMPOUNDS WHICH INHIBIT PLATELET DERIVED GROWTH FACTOR RECEPTOR ACTIVITY | UNIVERSITY OF CALIFORNIA | 2001-12-18 | — | — | US | disclosed |
| CN-1065744-C | Treatment of diseases associated with platelet derived growth factor such as cancer | SUGEN INC (US) | 2001-05-16 | — | — | CN | disclosed |
| EP-1000617-A2 | Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor | Sugen, Inc. (US) | 2000-05-17 | — | — | EP | disclosed |
| US-5990141-A | ADMINISTERING 5-METHYL-ISOXAZOLE-4-CARBOXYLIC ACID-N-(4-TRIFLUOROMETHYL)ANILIDE OR 2-CYANO-3-HYDROXY-N-(4-TRIFLUORO-METHYL)PHENYL-2-BUTENAMIDE; ANTITUMOR,-CARCINOGENIC AND PROLIFERATIVE AGENTS; KINASE INHIBITORS | SUGEN INC. (US) | 1999-11-23 | — | — | US | disclosed |
| US-5958959-A | ADMINISTERING 5-METHYLISOXAZOLE-4-CARBOXYLIC ACID-(4-TRIFLUOROMETHYL)ANILIDE OR 2-CYANO-3-HYDROXY-N-(4-(TRIFLUOROMETHYL)PHENYL)-2-BUTENAMIDE | SUGEN, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5932602-A | ANTIGROWTH AGENTS; ANTITUMOR AGENT; USING AN ISOOXIDAZOLE COMPOUND | SUGEN, INC. (US) | 1999-08-03 | — | — | US | disclosed |
| US-5700822-A | ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF ISOXAZOLE AMIDE DERIVATIOVE AND CYANO, HYDROXY, AROMATIC AMIDE DERIVATIVE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-12-23 | — | — | US | disclosed |
| US-5700823-A | ADMINISTERING 5-METHYLISOXAZOLE-4-CARBOXYLIC ACID-(4-TRIFLUOROMETHYL)-ANILIDE OR N-(4-TRIFLUOROMETHYLPHENYL)-2-CYANO-3-HYDROXYCROTONAMIDE | SUGEN, INC. (US) | 1997-12-23 | — | — | US | disclosed |
| EP-0804191-A1 | TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCERS USING INHIBITORS OF PLATELET DERIVED GROWTH RECEPTOR | Sugen, Inc. (US) | 1997-11-05 | — | — | EP | disclosed |
| CN-1128496-A | Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor | SUGEN INC (US) | 1996-08-07 | — | — | CN | disclosed |
| WO-1995019169-A2 | TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCER USING INHIBITORS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR | SUGEN, INC. (US) | 1995-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219210-A1 | Amidopyrazole Derivative | PTGER1, PTGS1, PTGER2 | EPHX1 1576/4885NAAA 438/4885CASP2 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.